Journals / Turkish Journal of Medical Sciences / 2022 / Cilt: 52 - Sayı: 1

Striatal dopaminergic neurons as a potential target for GDNF based ischemic stroke therapy

Pages
248–257
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, it seems that GDNF conducts several signaling pathways by acting on key transcription factors and shows its protective feature by fine-tuning the degeneration-related processes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Glial cell-line-derived neurotrophic factor (GDNF) is a well-known regulatory neurotrophic factor on dopaminergic neurons.
📊
Key Findings & Data:Materials and methods: Fourteen C57BL/6J male mice (8–10 weeks) were intracerebrally treated with lentiviral GDNF (Lv-GDNF) or vehicle.
💡
Conclusion & Impact:However, it seems that GDNF conducts several signaling pathways by acting on key transcription factors and shows its protective feature by fine-tuning the degeneration-related processes.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Glial cell-line-derived neurotrophic factor (GDNF) is a well-known regulatory neurotrophic factor on dopaminergic neurons. Several pathologies have been documented so far in case of any impairment in the dopaminergic system. This study aimed to investigate the potential protective role of lentiviral GNDF delivery on the small population of tyrosine hydroxylase (TH) positive dopamine producing striatal neurons after ischemic stroke. Materials and methods: Fourteen C57BL/6J male mice (8–10 weeks) were intracerebrally treated with lentiviral GDNF (Lv-GDNF) or vehicle. Ten days after injections, cerebral ischemia was induced by blockage of the middle cerebral artery. Animals were terminated 72 h after ischemia, and their brains were taken for histological and molecular investigations. Following confirmation of GDNF overexpression, TH immunostaining and immunoblotting were used to evaluate the role of GDNF on dopaminergic neurons. Next, Fluro Jade C staining was implemented to examine the degree of neuronal degeneration at the damaged parenchyma. Results: Neither the amount of TH positive dopaminergic neurons nor the expression of TH changed in the Lv-GDNF treated animals comparing to the vehicle group. On the other hand, GDNF exposure caused a significant increase in the expression of Nurr1, an essential transcription factor for dopaminergic neurons and Gap43, growth and plasticity promoting protein, in the ischemic striatum. Treatment with Lv-GDNF gave rise to a significant reduction in the number of degenerated neurons. Finally, enhanced GDNF expression also induced expression of an important stress-related transcription factor NF-κB as well as the nitric oxide synthase enzymes iNOS and nNOS in the contralesional hemisphere. Conclusion: Considering these results together, GDNF’s impact on the survival of striatal dopaminergic neurons is not outstanding for its neuroprotective role. However, it seems that GDNF conducts several signaling pathways by acting on key transcription factors and shows its protective feature by fine-tuning the degeneration-related processes.

🔖

Cite This Article

BEKER, M. Ç., ÇAĞLAYAN, A. B., KILIÇ, Ü., KILIÇ, E., BEKER, M., BOLAT, B., KÖSE, G. T. (2022). Striatal dopaminergic neurons as a potential target for GDNF based ischemic stroke therapy. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 1, 248–257. https://ajindex.com/articles/609287

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Mikulik R, Wahlgren N. Treatment of acute stroke: an update. Journal of Internal Medicine 2015
  2. 278(2):145-165. doi: 10.1111/joim.12387 2. Pena ID, Borlongan C, Shen G, Davis W. Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need. Journal of Stroke 2017
  3. 19(1):50-60. doi: 10.5853/jos.2016.01515 3. Leng T, Xiong ZG. Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges. Brain Circulation 2019
  4. 5(1):8-11. doi: 10.4103/bc.bc_36_18 4. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. The Lancet Neurology 2012
  5. 11(4):369-380. doi: 10.1016/S1474-4422(12)70039-X 5. Dimyan MA, Cohen LG. Neuroplasticity in the context of motor rehabilitation after stroke. Nature Reviews Neurology 2011
  6. 7(2):76-85. doi: 10.1038/nrneurol.2010.200 6. Xiao N, Le QT. Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. Archivum Immunologiae et Therapiae Experimentalis 2016
  7. 64(2):89-99. doi: 10.1007/ s00005-015-0376-4 7. Jin G, Omori N, Li F, Nagano I, Manabe Y et al. Protection against ischemic brain damage by GDNF affecting cell survival and death signals. Neurological Research 2003
  8. 25(3):249-253. doi: 10.1179/016164103101201454 8. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995
  9. 373(6512):335-339. doi: 10.1038/373335a0 9. d’Anglemont de Tassigny X, Pascual A, Lopez-Barneo J. GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease. Frontiers in Neuroanatomy 2015
  10. doi: 10.3389/fnana.2015.00010 10. Beker M, Caglayan AB, Beker MC, Altunay S, Karacay R et al. Lentivirally administered glial cell line-derived neurotrophic factor promotes post-ischemic neurological recovery, brain remodeling and contralesional pyramidal tract plasticity by regulating axonal growth inhibitors and guidance proteins. Experimental Neurology 2020
  11. 113364. doi: 10.1016/j. expneurol.2020.113364 11. Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T et al. alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Science Translational Medicine 2012
  12. 4(163):163ra156. doi: 10.1126/ scitranslmed.3004676 12. Su X, Fischer DL, Li X, Bankiewicz K, Sortwell C